Switch theme
Sign up to access all valuation multiples
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
1994
86
LTM Revenue $9.6M
LTM EBITDA -$12.0M
-$9.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medigene has a last 12-month revenue of $9.6M and a last 12-month EBITDA of -$12.0M.
In the most recent fiscal year, Medigene achieved revenue of $6.5M and an EBITDA of -$15.7M.
Medigene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medigene valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $33.6M | $6.5M | XXX | XXX | XXX |
| Gross Profit | $9.8M | $31.4M | XXX | XXX | XXX |
| Gross Margin | 29% | 485% | XXX | XXX | XXX |
| EBITDA | $14.1M | -$15.7M | XXX | XXX | XXX |
| EBITDA Margin | 42% | -242% | XXX | XXX | XXX |
| Net Profit | -$10.7M | -$8.9M | XXX | XXX | XXX |
| Net Margin | -32% | -138% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Medigene's stock price is EUR 0 (or $0).
Medigene has current market cap of EUR 3.1M (or $3.3M), and EV of -EUR 8.4M (or -$9.0M).
See Medigene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$9.0M | $3.3M | XXX | XXX | XXX | XXX | $-1.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Medigene has market cap of $3.3M and EV of -$9.0M.
Medigene's trades at -0.9x LTM EV/Revenue multiple, and 0.7x LTM EBITDA.
Analysts estimate Medigene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medigene and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$9.0M | XXX | XXX | XXX |
| EV/Revenue | -1.4x | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedigene's NTM/LTM revenue growth is 73%
Medigene's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Medigene's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medigene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medigene and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -81% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -242% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -211% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -169% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 71% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 191% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 340% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medigene acquired XXX companies to date.
Last acquisition by Medigene was XXXXXXXX, XXXXX XXXXX XXXXXX . Medigene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medigene founded? | Medigene was founded in 1994. |
| Where is Medigene headquartered? | Medigene is headquartered in Germany. |
| How many employees does Medigene have? | As of today, Medigene has 86 employees. |
| Is Medigene publicy listed? | Yes, Medigene is a public company listed on ETR. |
| What is the stock symbol of Medigene? | Medigene trades under MDG1 ticker. |
| When did Medigene go public? | Medigene went public in 2000. |
| Who are competitors of Medigene? | Similar companies to Medigene include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Medigene? | Medigene's current market cap is $3.3M |
| What is the current revenue of Medigene? | Medigene's last 12-month revenue is $9.6M. |
| What is the current EBITDA of Medigene? | Medigene's last 12-month EBITDA is -$12.0M. |
| What is the current EV/Revenue multiple of Medigene? | Current revenue multiple of Medigene is -0.9x. |
| What is the current EV/EBITDA multiple of Medigene? | Current EBITDA multiple of Medigene is 0.7x. |
| What is the current revenue growth of Medigene? | Medigene revenue growth between 2023 and 2024 was -81%. |
| Is Medigene profitable? | Yes, Medigene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
